Howard Burris

Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas

Howard Burris, Ingo K. Mellinghoff, Elizabeth A. Maher et al. · Molecular Cancer Therapeutics · 2015 · 38 citations

Medicine, Molecular Biology, Oncology +12

Abstract CT153: First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

Gerald S. Falchook, Manish R. Patel, Jeffrey R. Infante et al. · Cancer Research · 2017 · 24 citations

Medicine, Oncology, Pharmacology +15

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Huali Wu, Jeffrey R. Infante, Vicki L. Keedy et al. · International Journal of Nanomedicine · 2015 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS

Ingo K. Mellinghoff, Mehdi Touat, Elizabeth A. Maher et al. · Neuro-Oncology · 2016 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters et al. · Neuro-Oncology · 2018 · 15 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13